# Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets

> **NCT01632722** · PHASE2 · COMPLETED · sponsor: **Yonsei University** · enrollment: 79 (actual)

## Conditions studied

- Colorectal Cancer
- Liver Metastasis

## Interventions

- **DRUG:** Bevacizumab, mFOLFOX, FOLFIRI
- **DRUG:** Bevacizumab, mFOLFOX, FOLFIRI

## Key facts

- **NCT ID:** NCT01632722
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2018-05
- **Final completion:** 2018-06
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2018-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01632722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01632722, "Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01632722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*